INVERSAGO-PHARMA-INC.
29.9.2020 14:02:30 CEST | Business Wire | Press release
Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has initiated a Phase 1 clinical trial of INV-101, the Company’s peripherally-acting CB1 blocker, which is being developed for the treatment of Prader-Willi syndrome (PWS) and non-alcoholic steatohepatitis (NASH).
The trial will evaluate the safety, tolerability and pharmacokinetics of INV-101. Recruitment is ongoing and will enroll healthy participants in Canada, from 18 to 55 years old. Subjects will initially be randomized to receive a single dose of placebo or one of 5 dose levels of INV-101.
“With the launch of this first-in-human trial, Inversago is now a clinical-stage company, and confirms its lead in the comeback of small molecule peripheral CB1 blockers”, said François Ravenelle, PhD, CEO and founder of Inversago Pharma.
“Dosing of our first patient with INV-101 represents an important milestone to accomplish the Company’s vision: offering a potentially meaningful therapeutic option to underserved patient populations, like in PWS and NASH" said Carlo Incerti, M.D., Chairman of the Board of Inversago. "This study is the first step in the clinical development of our peripherally-acting CB1 blockers, and we expect it to provide important information about its safety and pharmacokinetics profile", concluded Dr. Incerti.
The Company’s second program, INV-202, is presently in IND-enabling preclinical studies, while other programs are in earlier stages of development. With its current pipeline, Inversago is well positioned to fully exploit peripheral CB1 blockade for a wide range of underserved metabolic indications with differentiated products.
About INV-101
INV-101 is a first-in-class, small molecule CB1 inverse agonist / antagonist being developed by Inversago for the treatment of PWS and NASH. It is specifically designed to interact with peripheral CB1 receptors located in the gastro-intestinal tract, liver, pancreas, adipose tissues, muscles, lungs and other organs, thus aiming at a safe and effective therapeutic approach without the known liabilities of centrally-acting CB1 blockers. The peripheral CB1 blockade is a well-documented pathway, linked to many clinically meaningful metabolic benefits.
About Inversago Pharma
Inversago Pharma is a clinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Prader-Willi Syndrome (PWS), non-alcoholic steatohepatitis (NASH), type 1 diabetes (T1D) and diabetic nephropathy. For more information, visit inversago.com .
Picture of our CEO and company logotype available for download at: inversago.com/en/media/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200929005408/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hightouch Partners with Independent Media to Activate Reader and Commercial Data27.10.2026 17:01:00 CET | Press release
The partnership will help Independent Media deliver more relevant reader engagement, build premium advertising audiences, and support affiliate and e-commerce growth. Hightouch, the leading agentic marketing platform, today announced a partnership with Independent Media, publisher of The Independent. Independent Media will use Hightouch to connect its customer data to marketing tools. With Hightouch, the company will send readers more relevant membership and subscription offers, build stronger audiences for its advertising partners, and grow its affiliate and e-commerce business. “Deepening customer relationships and delivering real value to our commercial partners requires moving seamlessly from insight to action,” said Krishan Gandhi, Director of Data Intelligence and Monetisation at Independent Media. “Partnering with Hightouch allows us to utilise our warehouse data directly into our engagement tools, powering real-time, omnichannel journey orchestration, while enabling us to build
IFF Identifies Ten Consumer Moments Reshaping Food and Beverage Innovation in the GLP-1 Era27.10.2026 16:00:00 CET | Press release
New research reveals how smaller, more intentional eating occasions are creating new opportunities for nutrition, flavor and renewed enjoyment. IFF (NYSE: IFF)—a global leader in flavors, fragrances and health and biosciences, today launched its latest report, “GLP-1 Consumer Moments of Opportunity.” The report uncovers ten emerging consumer moments that reflect the changing needs of consumers using GLP-1 medications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026614988/en/ New report from IFF uncovers ten emerging consumer moments that reflect the changing needs of consumers using GLP-1 medications. “What GLP-1 users need from food and beverage products depends on the moment, and those needs can change many times throughout the day,” said Yuvraj Arora, president of IFF Taste. “The most successful innovations will be designed around the occasions that matter most to consumers, delivering the right balance of nutrition
Phison Receives Micron Global Supplier Awards27.10.2026 15:00:00 CET | Press release
Phison Electronics (8299TT), a global leader in NAND flash controllers and storage solutions, is honored to announce that it was presented with Outstanding Supplier Performance Awards in the Semiconductor category and the Best in Quality – Assembly and Test categoryat the Micron Supplier Day 2026. The event, held in Boise, Idaho, United States was attended by top-level management of Micron and its suppliers, including Phison. The awards highlight our commitment to excellence in quality, innovation and collaboration with Micron, a global leader in semiconductor memory and storage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027158504/en/ Phison wins Outstanding Supplier Performance Award in Semiconductor category and the Best in Quality – Assembly and Test category at the Micron Supplier Day 2026 “Receiving our third Micron Supplier Award in a row is a tremendous honor and a testament to the strength of our partnership
MUFG Investor Services Appoints McAllister Kirschner Chief Executive Officer27.10.2026 14:15:00 CET | Press release
MUFG Investor Services today announced the appointment of McAllister (Mac) Kirschner as Chief Executive Officer, effective immediately. John Sergides has stepped down as Chief Executive Officer of MUFG Investor Services for health-related reasons. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027545977/en/ McAllister (Mac) Kirschner Appointed Chief Executive Officer of MUFG Investor Services Kirschner has served as Chief Operating Officer of MUFG Investor Services since 2018, overseeing business and banking operations across public and private markets. He joined MUFG Investor Services in 2016 and previously served as Global Head of Relationship Management, bringing extensive knowledge of the business, its clients, and operations. Before joining MUFG Investor Services, Kirschner was a Managing Director in BlackRock’s Global Fund Services business, where he led teams responsible for shareholder servicing, fund administrati
FEINDEF 27 Has Already Booked 94% of Its Exhibition Space Seven Months Ahead of the Event27.10.2026 14:03:00 CET | Press release
The International Defence and Security Exhibition of Spain (FEINDEF 27) has booked 94% of its exhibition space for 18 to 20 May 2027 at IFEMA Madrid, reflecting strong demand and interest among companies and institutions across the sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027170443/en/ Ángel Olivares, President of the Feindef Foundation Fundación Feindef announced the figure on Monday at the official presentation of the exhibition's fifth edition, held at Madrid's Rafael del Pino Auditorium. The fair is expected to cover more than 89,000 square metres, 46% more than in 2025. More than 746 exhibitors have been confirmed, up 19% on the previous edition. Of these, 37% are first-time participants and over 250 are international exhibitors, accounting for 33% of the total. The event will feature 14 international pavilions, strengthening its international reach as the defence and security industry gains prominence
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom